Heart failure & cardiomyopathies
Papillary Muscle Delayed Hyperenhancement: Prevalence and Clinical Implications in a Large Population With Dilated Cardiomyopathy
Authors' conclusion
The combined presence of myocardial and papHE was independently associated with adverse outcomes.
Study context
- Population
- Patients with nonischemic dilated cardiomyopathy undergoing late gadolinium enhancement CMR
- Participants
- 528 patients
- Exposure
- Papillary muscle HE and/or myocardial HE vs neither
- Outcome
- All-cause mortality, SCD, life-threatening arrhythmia, and HF hospitalization
- Follow-up
- Median 6.1 years (IQR: 3.7-9.7 years)
Main finding
As reported in the abstract
papHE and myocardial HE vs No papHE, no myocardial HEHazard ratio (95% CI)
All-cause mortality
2.33(1.26–4.30)
SCD
3.77(1.59–8.94)
Life-threatening arrhythmia
3.94(1.34–11.58)
HF hospitalization
2.97(1.30–6.80)
Observational data: associations, not effects.
Further findings
Prevalence of papHE
- papHE present
- 131 patients (25%)
Original publication
Papillary Muscle Delayed Hyperenhancement: Prevalence and Clinical Implications in a Large Population With Dilated Cardiomyopathy. JACC Adv. Published 13 July 2024. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →